This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced NSCLC treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.
There is one SNP
Inclusion Criteria: - Adult (aged ≥18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV); - Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment; - Initiating dacomitinib as first-line treatment after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy); Exclusion Criteria: - Enrolled in any interventional clinical study or trial (however, patients enrolled in non-interventional, real world study may still be included). --- L858R ---